Results from automatic estrogen receptor (ER) and progesterone receptor (PR) tests on breast core needle biopsies in patients with ductal carcinoma in situ (DCIS) did not modify the next step in management, according to a recent study.
Pedram Argani, MD, a professor of pathology and oncology at the Johns Hopkins Hospital, in Baltimore, was inspired to conduct the review of 58 core needle biopsy specimens because he said he often consults on cases of breast core needle biopsy